Scott M. Giacobello sold $8,585 of WHWK
CHIEF FINANCIAL OFFICER at Aadi Bioscience, Inc.. 2,594 shares at an average of $3.31, traded Mar 2, 2026, filed Mar 10, 2026.
Score components
- +22RoleCFO
- 0Trade size$9k at market
- 0Share of holdings soldSold 8.5% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -11.9%, 3m +4.7%, 6m +8.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001754154-26-000002, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 1, 2026 | MOption exercise Common Stock | +6,750 | - | - | 30,694 | Mar 10, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock | -2,594 | $3.31 | $8,585 | 28,100 | Mar 10, 2026 |
| Mar 1, 2026 | MOption exercise Restricted Stock Unitsderivative | -6,750 | $0.00 | $0 | 13,500 | Mar 10, 2026 |
Related signals
Other insiders at Aadi Bioscience, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 70Notable | Aadi Bioscience, Inc. | Scott M. Giacobello CHIEF FINANCIAL OFFICER | $882k 218,600 shares | -43% | |
| 52Moderate | Aadi Bioscience, Inc. | Bryan Ball See remarks | $428k 118,849 shares | -23% | |
| 42Moderate | Aadi Bioscience, Inc. | Bryan Ball See remarks | $201k 56,596 shares | -10% | |
| 47Moderate | Aadi Bioscience, Inc. | David James Lennon CHIEF EXECUTIVE OFFICER | $49k 14,500 shares | -3% | |
| 74Notable | Aadi Bioscience, Inc. | David James Lennon CHIEF EXECUTIVE OFFICER | $900k 260,427 shares | -33% | |
| 35Weak | Aadi Bioscience, Inc. | David James Lennon CHIEF EXECUTIVE OFFICER | $93k 26,858 shares | -3% | |
| 15Weak | Aadi Bioscience, Inc. | Bryan Ball See remarks | $6,070 1,834 shares | -1% | |
| 30Weak | Aadi Bioscience, Inc. | David James Lennon CHIEF EXECUTIVE OFFICER | $17k 5,100 shares | -10% | |
| 15Weak | Aadi Bioscience, Inc. | Bryan Ball See remarks | $5,045 2,147 shares | -2% | |
| 30Weak | Aadi Bioscience, Inc. | David James Lennon CHIEF EXECUTIVE OFFICER | $13k 5,690 shares | -15% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.